Affluent Medical (AFME) | Financial Analysis & Statements
Affluent Medical S.A. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
59.8M
Total Liabilities
38.7M
Shareholders Equity
21.1M
Debt to Equity
1.83
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
Affluent Medical Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 4.1M | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | 3.3M | 2.1M | 2.4M | 2.5M | 3.1M |
| Gross Profit | 856.0K | -2.1M | -2.4M | -2.5M | -3.1M |
| Gross Margin % | 20.8% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 94.0K | 72.0K | 52.0K | 23.0K | 9.0K |
| Selling, General & Administrative | 163.0K | 149.0K | 152.0K | 1.2M | 69.0K |
| Other Operating Expenses | 5.6M | 4.6M | 3.9M | 3.1M | 3.2M |
| Total Operating Expenses | 5.8M | 4.8M | 4.1M | 4.3M | 3.3M |
| Operating Income | -14.6M | -15.4M | -14.3M | -13.3M | -12.6M |
| Operating Margin % | -355.4% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | 0 | 0 |
| Interest Expense | 516.0K | 409.0K | 710.0K | 3.1M | 2.2M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -14.9M | -15.8M | -15.4M | -15.3M | -14.5M |
| Income Tax | -142.0K | -150.0K | -173.0K | -437.0K | -209.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -14.7M | -15.7M | -15.2M | -14.8M | -14.3M |
| Net Margin % | -357.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -12.2M | -13.0M | -12.2M | -10.8M | -10.5M |
| EPS (Basic) | €-0.38 | €-0.51 | €-0.81 | €-0.88 | €-1.18 |
| EPS (Diluted) | €-0.38 | €-0.51 | €-0.81 | €-0.88 | €-1.18 |
| Basic Shares Outstanding | 39167409 | 30740373 | 18886577 | 16873582 | 12180441 |
| Diluted Shares Outstanding | 39167409 | 30740373 | 18886577 | 16873582 | 12180441 |
Income Statement Trend
Affluent Medical Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.2M | 1.7M | 2.6M | 11.4M | 5.6M |
| Short-term Investments | 5.4M | - | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | - | -1.0K |
| Total Current Assets | 12.2M | 5.8M | 7.2M | 14.7M | 7.9M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 235.0K | 892.0K | 213.0K | 283.0K | 247.0K |
| Goodwill | 79.5M | 81.4M | 83.2M | 85.1M | 87.0M |
| Intangible Assets | 15.1M | 17.0M | 18.8M | 20.7M | 22.6M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | -1.0K | -1.0K | 1.8M |
| Total Non-Current Assets | 48.7M | 50.9M | 52.8M | 55.4M | 56.9M |
| Total Assets | 60.9M | 56.7M | 60.0M | 70.0M | 64.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 4.7M | 3.4M | 3.0M | 1.8M | 2.4M |
| Short-term Debt | 1.7M | 1.8M | 2.1M | 2.8M | 3.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 30.0K | 37.0K | 108.0K | 270.0K | 438.0K |
| Total Current Liabilities | 9.5M | 8.4M | 8.6M | 7.3M | 9.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 14.6M | 15.1M | 15.7M | 17.0M | 17.0M |
| Deferred Tax Liabilities | 1.4M | 1.6M | 1.8M | 2.0M | 2.4M |
| Other Non-Current Liabilities | -2.0K | - | - | -55.2M | 2.0K |
| Total Non-Current Liabilities | 21.1M | 16.7M | 17.6M | 19.2M | 19.8M |
| Total Liabilities | 30.6M | 25.2M | 26.2M | 26.5M | 29.5M |
| Equity | |||||
| Common Stock | 3.9M | 3.1M | 20.8M | 18.2M | 15.3M |
| Retained Earnings | -70.9M | -57.7M | -70.6M | -55.2M | -42.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 30.3M | 31.5M | 33.8M | 43.5M | 35.3M |
| Key Metrics | |||||
| Total Debt | 16.3M | 16.8M | 17.7M | 19.8M | 20.8M |
| Working Capital | 2.6M | -2.6M | -1.5M | 7.4M | -1.9M |
Balance Sheet Composition
Affluent Medical Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -14.7M | -15.7M | -15.2M | -14.8M | -14.3M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 778.0K | 731.0K | 146.0K | 42.0K | 959.0K |
| Working Capital Changes | -930.0K | 560.0K | -1.4M | -1.3M | 1.7M |
| Operating Cash Flow | -14.5M | -14.0M | -15.4M | -13.3M | -9.9M |
| Investing Activities | |||||
| Capital Expenditures | -147.0K | -171.0K | -146.0K | -334.0K | -304.0K |
| Acquisitions | 5.0M | 0 | - | - | - |
| Investment Purchases | -10.5M | 0 | - | - | - |
| Investment Sales | 5.2M | 0 | - | - | - |
| Investing Cash Flow | -480.0K | -171.0K | -146.0K | -160.0K | -304.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 0 | 0 | 795.0K | 6.1M |
| Debt Repayment | -740.0K | -866.0K | -2.4M | -5.2M | -2.0M |
| Financing Cash Flow | 11.7M | 11.7M | 2.9M | 19.1M | 13.7M |
| Free Cash Flow | -11.5M | -12.2M | -11.2M | -12.7M | -9.2M |
| Net Change in Cash | -3.2M | -2.4M | -12.6M | 5.6M | 3.5M |
Cash Flow Trend
Affluent Medical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-8.37
Forward P/E
-6.32
Price to Book
5.24
Price to Sales
20.97
PEG Ratio
-6.32
Profitability Ratios
Profit Margin
-279.97%
Operating Margin
-1,575.56%
Return on Equity
-62.51%
Return on Assets
-16.07%
Financial Health
Current Ratio
1.07
Debt to Equity
110.96
Beta
0.79
Per Share Data
EPS (TTM)
€-0.36
Book Value per Share
€0.54
Revenue per Share
€0.13
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AFME | 122.2M | -8.37 | 5.24 | -62.51% | -279.97% | 110.96 |
| Eurobio Scientific | 229.6M | 108.64 | 1.33 | 2.24% | 2.90% | 0.19 |
| Median Technologies | 188.6M | -3.61 | - | 74.31% | -94.04% | -1.15 |
| Guerbet S.A | 127.3M | 13.77 | 0.47 | -34.58% | -13.56% | 169.65 |
| Mauna Kea | 37.4M | -1.17 | -1.37 | 42.66% | -127.03% | -1.35 |
| Diagnostic Medical | 34.5M | -133.50 | 2.16 | -11.62% | -3.37% | 138.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.